228 related articles for article (PubMed ID: 12559522)
1. Treatment of head and neck cancer with CHART and nimorazole: phase II study.
Henk JM; Bishop K; Shepherd SF
Radiother Oncol; 2003 Jan; 66(1):65-70. PubMed ID: 12559522
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer.
Cottrill CP; Bishop K; Walton MI; Henk JM
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):807-10. PubMed ID: 9845101
[TBL] [Abstract][Full Text] [Related]
3. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Metwally MA; Frederiksen KD; Overgaard J
Acta Oncol; 2014 May; 53(5):654-61. PubMed ID: 24328536
[TBL] [Abstract][Full Text] [Related]
4. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
5. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
[TBL] [Abstract][Full Text] [Related]
6. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers.
Dobrowsky W; Naudé J
Radiother Oncol; 2000 Nov; 57(2):119-24. PubMed ID: 11054514
[TBL] [Abstract][Full Text] [Related]
7. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
Overgaard J; Hoff CM; Hansen HS; Specht L; Overgaard M; Lassen P; Andersen E; Johansen J; Andersen LJ; Evensen JF; Alsner J; Grau C
Radiother Oncol; 2018 Apr; 127(1):12-19. PubMed ID: 29523409
[TBL] [Abstract][Full Text] [Related]
8. Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial.
Hassan Metwally MA; Jansen JA; Overgaard J
Clin Oncol (R Coll Radiol); 2015 Mar; 27(3):168-75. PubMed ID: 25530485
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
10. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer.
Dobrowsky W; Naudé J; Widder J; Dobrowsky E; Millesi W; Pavelka R; Grasl C; Reichel M
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):803-6. PubMed ID: 9845100
[TBL] [Abstract][Full Text] [Related]
11. A systematic overview of radiation therapy effects in head and neck cancer.
Zackrisson B; Mercke C; Strander H; Wennerberg J; Cavallin-Ståhl E
Acta Oncol; 2003; 42(5-6):443-61. PubMed ID: 14596506
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
13. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
14. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
15. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.
Poulsen MG; Denham JW; Peters LJ; Lamb DS; Spry NA; Hindley A; Krawitz H; Hamilton C; Keller J; Tripcony L; Walker Q
Radiother Oncol; 2001 Aug; 60(2):113-22. PubMed ID: 11439206
[TBL] [Abstract][Full Text] [Related]
16. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
Huguenin P; Beer KT; Allal A; Rufibach K; Friedli C; Davis JB; Pestalozzi B; Schmid S; Thöni A; Ozsahin M; Bernier J; Töpfer M; Kann R; Meier UR; Thum P; Bieri S; Notter M; Lombriser N; Glanzmann C
J Clin Oncol; 2004 Dec; 22(23):4665-73. PubMed ID: 15534360
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).
Thomson DJ; Slevin NJ; Baines H; Betts G; Bolton S; Evans M; Garcez K; Irlam J; Lee L; Melillo N; Mistry H; More E; Nutting C; Price JM; Schipani S; Sen M; Yang H; West CM;
Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):771-782. PubMed ID: 38072326
[TBL] [Abstract][Full Text] [Related]
18. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer.
Nordsmark M; Overgaard J
Acta Oncol; 2004; 43(4):396-403. PubMed ID: 15303502
[TBL] [Abstract][Full Text] [Related]
19. NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer.
Thomson D; Yang H; Baines H; Miles E; Bolton S; West C; Slevin N
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):344-7. PubMed ID: 24685344
[No Abstract] [Full Text] [Related]
20. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.
Overgaard J; Hansen HS; Specht L; Overgaard M; Grau C; Andersen E; Bentzen J; Bastholt L; Hansen O; Johansen J; Andersen L; Evensen JF
Lancet; 2003 Sep; 362(9388):933-40. PubMed ID: 14511925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
